Clinical Trial

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

Study acronym: PECHORA
Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.
Protocol Amendment History 6 changes
critical Trial completed 2026-07-28
notable Enrollment increased: 7 -> 8 participants 2026-07-28
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-02
notable Enrollment reduced: 12 -> 7 participants 2026-07-02
notable Primary completion pushed: 2026-05-26 -> 2026-07-13 2026-04-28
minor Completion pushed: 2026-05-26 -> 2026-07-13 2026-04-28
Trial Details
NCT Number NCT07069725
Lead Sponsor AstraZeneca
Collaborators: CTC Clinical Trial Consultants AB, Karolinska Institutet
Conditions Liver Fibrosis, Hepatic Cirrhosis
Enrollment 8 participants
Start Date 2025-05-26
Primary Completion 2026-07-02 (estimated)
Study Completion 2026-07-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-27